New Immunotherapy Treatment Promising for NSCLC
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being...
Read More
Latest – ASCO – Lung Cancer
MET Mutation Inhibitor Associated with Tumor Reductions in NSCLC
Targeting tumor driver appears effective in half of NSCLC patients Treatment with the...
Read More
CASPIAN Trial Update: Phase 3 Results & Perspectives
Updated findings from the phase 3 CASPIAN trial presented at the 2020 American Society of Clinical...
Read MoreNivolumab and Chemo Significantly Improved Survival in ES-SCL
In the phase 2 ECOG-ACRIN EA5161 trial, a significant improvement in both progression-free and overall survival was observed from adding the checkpoint inhibitor nivolumab to chemotherapy (cisplatin/carboplatin with etoposide)...
Read More
MET Inhibitor, Capmatinib, Inhibits Kinase Activity of the METex14
MET-mutations and MET-amplifications are reported in 1-6% of patients with NSCLC. In the ongoing,...
Read More
New Second-Line Treatment Option for Malignant Pleural Mesothelioma?
To date, second-line chemotherapy is not the standard of care in patients with malignant pleural...
Read More T-DXd Demonstrates Meaningful Clinical Activity in HER2-mNSCLC
In an interim analysis of the DESTINY-Lung01 trial, trastuzumab deruxtecan (T-DXd) demonstrated...
Read More
Addition of Chemo to Durvalumab/Tremelimumab Does Not Improve OS
In the phase 3 CCTG BR.34 trial, no additional effect on overall survival (OS) was observed by...
Read More
Ipilimumab/nivolumab given concomitantly with two cycles of chemotherapy demonstrated prolonged overall survival
Ipilimumab/nivolumab given concomitantly with two cycles of chemotherapy demonstrated prolonged...
Read More- 1
- 2